MAPT and amyloidosis: Moreover, it also reduced APP, Aβ level and amyloid plaque burden.110 These studies demonstrating positive effects of tau immunotherapy reducing amyloid burden provide a promising avenue to target both tau and Aβ immunotherapies in combination.